Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia ; volume:34 ; number:12 ; day:21 ; month:11 ; year:2017 ; pages:2585-2600 ; date:12.2017
Advances in therapy ; 34, Heft 12 (21.11.2017), 2585-2600, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Skelly, Adrian
- Beteiligte Personen und Organisationen
-
Carius, Hans-Joachim
Bezlyak, Vladimir
Chen, Fred K.
SpringerLink (Online service)
- DOI
-
10.1007/s12325-017-0624-6
- URN
-
urn:nbn:de:1111-2018020213359
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Skelly, Adrian
- Carius, Hans-Joachim
- Bezlyak, Vladimir
- Chen, Fred K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration